Sygnature Discovery has launched an in vivo inflammation model, that the company says is ‘exciting but only the beginning’ of understanding life-limiting neuroinflammatory conditions.
Therapies for cancer, autoimmune diseases, inflammatory diseases and other drug markets are all siloed, despite new research emerging that shows potential connections between them. In order to create more effective therapeutics, we need to pull from research...